Company intelligence / Profile preview
BrainEver
Paris, Île-de-France, Francebrainever.fr ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
BrainEver has demonstrated in preclinical models that recombinant human Engrailed 1 can protect motor neurons, restore muscle function, and prevent neuronal death in ALS models. The lead candidate BREN‑02 received FDA Orphan Drug Designation for ALS. The company has secured significant EU funding to advance into clinical trials targeting ALS and Parkinson’s Disease.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Recombinant proteins (homeoproteins, specifically Engrailed 1)Biologics
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Collaboration with 3P Biopharmaceuticals for GMP manufacturing of recombinant human Engrailed‑1 for clinical use in ALS trialsCo-funding from the European Union/EIC Accelerator grant
Beyond the preview
Go deeper on BrainEver.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BrainEver.